Key result
Serotonergic medications are linked to ~3.3-fold higher odds of drug-induced valvular heart disease.
Why the study?
Serotonergic appetite suppressants and ergot-derived dopamine agonists have been linked to valvular heart disease, prompting a synthesis of evidence on medications affecting serotonergic pathways.
Do medications affecting serotonergic pathways and ergot-derived dopamine agonists increase the risk of drug-induced valvular heart disease compared to unexposed or control groups?
Meta-Analysis
Yes
Do medications affecting serotonergic pathways and ergot-derived dopamine agonists increase the risk of drug-induced valvular heart disease compared to unexposed or control groups?
This meta-analysis confirms a strong association between serotonergic medications and ergot-derived dopamine agonists (particularly at higher doses used for Parkinson's disease) and valvular heart disease, while highlighting the need for surveillance of widely used SSRIs and recreational MDMA that act on similar serotonergic pathways.
Answers are grounded in this paper and cite their sources.
Supports valvular surveillance in exposed patients; confirms associations and extends evidence to widely used agents.
OBJECTIVE: Serotonergic appetite suppressants and ergot-derived dopamine agonists have been associated with drug-induced valvular heart disease. The purpose of this meta-analysis is to synthesise the current evidence of a link between several medications affecting sertonergic pathways and valvular heart disease. METHODS: PubMed was searched to identify studies evaluating an association between medications with serotonergic activity and cardiac valvular pathology. Case reports, uncontrolled studies and in vitro studies were excluded. Relevant studies were assessed for quality and potential bias; those of adequate quality were included in a quantitative synthesis. Sensitivity analyses were conducted, and potential publication bias was examined. RESULTS: There was a consistent, significant relationship between certain medications and heart valve disease, including serotonergic medications (OR 3.30, 95% CI 1.99 to 5.49) and dopaminergic medications (OR 2.56, 95% CI 1.68 to 3.91). Subanalyses, including analyses that limited exposure to a single medication or effects to a single heart valve were also consistently significant. Most studies were retrospective or observational in nature, with a higher risk of selection and presentation biases. There was significant heterogeneity and variability between studies, particularly when it came to dose and duration of exposure. CONCLUSIONS: There was a consistent, significant association between many medications that affect serotonergic pathways and valvular heart disease. Although many of these medications have been withdrawn from the market, some small studies suggest that recreational drug 3,4-methylenedioxymethamphetamine and widely prescribed selective serotonin reuptake inhibitors may affect similar pathways.
No takes yet. Share an insight, caveat, or question.
Fortier et al. (2019) conducted a meta-analysis in Drug-induced valvular heart disease (DI-VHD). Medications affecting serotonergic pathways (serotonergic appetite suppressants, SSRIs, MDMA) and ergot-derived dopamine agonists with 5HTR2B affinity vs. Unexposed control groups, non-ergot-derived dopamine agonists, or placebo was evaluated on Drug-induced valvular heart disease (defined by CDC and FDA criteria as mild or greater aortic valve regurgitation or moderate or greater mitral or tricuspid valve regurgitation) (OR 3.30, 95% CI 1.99 to 5.49). Serotonergic medications (OR 3.30, 95% CI 1.99-5.49) and dopaminergic medications (OR 2.56, 95% CI 1.68-3.91) were significantly associated with drug-induced valvular heart disease.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: